November 14, 2019

In Vivo

Market Access 2020: Understanding US Payer Expectations

Consolidation on the payer side is changing the dynamics of success in health care.  Principals at Real Endpoints LLC examine

June 11, 2019

Elsevier

Are Payers Ready, Willing, and Able to Provide Access to New Durable Gene Therapies?

Access to new gene therapies may be impacted by payer ability to absorb the cost of coverage. Payers are open to innovative financing models that improve financial predictability and reward clinical performance.

March 1, 2019

In Vivo

Paying for Pharmaceutical Value: The Problem of a One-Size-Fits-All Definition

Combining a set of tailored, regularly updated value assessments with risk-sharing contracts allows us to deal with evidentiary uncertainty by

February 13, 2019

AJMC

Examining New Payment Ideas for Curative Therapies

How can the health industry ensure that cutting-edge gene therapies and other curative treatments get to the patients that need them, without leaving payers financially exposed? Jane F. Barlow, MD, MPH, MBA, was a speaker at the FoCUS (Financing and Reimbursement of Cure in US) Project at MIT, during the session "Putting Theory into Practice" she was quoted saying the “accessibility issue lies largely with payers.” All payers are different, and “a lot has to do with how they manage risk in their population as well as the regulatory constraints."

January 28, 2019

STAT

AstraZeneca strikes a ‘novel’ deal with Medicare plan to lower patient out-of-pocket costs

In a novel bid to lower medicine costs, a drug maker has agreed to adjust the discounts that a Medicare Part D plan will receive for a treatment based on how patients respond — and the deal automatically lowers out-of-pocket costs for patients, as well. “One of the major problems we have in getting drug therapy used by people who really need it is that, for those people who are on Medicare, who have to pay co-insurance or copays, there is no really good way for manufacturers to provide copay assistance, because they are not allowed to do so,” said Roger Longman.

November 18, 2018

STAT

What rebates? Express Scripts touts a new plan to appease critics of the opaque drug-pricing system

Amid national angst over prescription drug pricing, Express Scripts is touting a new scheme it says will lessen the behind-the-scenes role that rebates play in rising costs. In effect, Express Scripts would create a two-tier system for its customers which could choose between a formulary with a high list price and high rebate, or the newer plan that will offer a lower list price and lower or no rebate.

November 5, 2018

BioCentury

Backing into Value with Part B

Jeff Berkowitz, CEO, Real Endpoints' is quoted, "It becomes a global index that reflects the value as seen by number of different entities against all of the other choices they need to make from a health delivery perspective."

October 17, 2018

Scrip Pharma Intelligence

Teva Stands By Migraine Strategy After Ajovy Misses Boat On Express Scripts Deal

Agreement between Amgen/Novartis and Eli Lilly with Express Scripts on new migraine drugs could spur more demand by payers for simple, value-based outcomes deals. The news is a big blow for Ajovy (fremanezumab-vfrm), as Express Scripts covers 30% of commercially insured patients in the US

July 2, 2018

BioCentury

Defining access potential – Before it’s too late

Confirmation bias: when innovators believe in a drug, find the evidence to support its value, and dismiss or ignore the facts challenging their preferred story. Industry and its investors need a clear, objective lens through which they can burn away confirmation bias and see the likely access barriers their drugs will face once approved

June 18, 2018

Depression Rising (Again): Turning the Corner in Psychiatry’s Most Burdensome Disorder

For all of the millions who suffer from depression, the biological underpinnings of clinical depression are still not fully understood. With several high profile approval decisions and possible launches on the horizon, the stage is thus set for an emerging commercial case characterized by a new wave of effective anti-depressants, an increasingly influential assortment of payers and practitioners with generic but often ineffectual pharmacotherapy options at their disposal, and of course patients with an unabating level of need and strikingly high placebo response-rates. How will it play out?

March 26, 2018

“Manufacturers are realizing that this is going to be a feature of the landscape and some have begun to think about it as a mutual opportunity.” Steven Pearson, ICER

The Institute for Clinical and Economic Review is rapidly becoming the closest thing the U.S. has to an HTA agency. The credibility afforded by ICER’s independent status, and its inclusion of diverse stakeholder views in constructing its cost effectiveness analyses, are leading payers and PBMs to use the analyses to establish coverage criteria, determine formulary placement and negotiate discounts from drug manufacturers.

February 20, 2018

Harvard Pilgrim and Illumina sign first-of-its-kind value-based contract

Real Endpoints plays a valuable role in orchestrating a first-of-its-kind value-based contract between Harvard Pilgrim and Illumina by introducing the parties and helping to craft the deal structure. Real Endpoints will provide all analytics and financial reconciliation for the initiative.

January 11, 2018

Ophthalmology Innovation Summit

Drug Pricing Pro Roger Longman of Real Endpoints Says Spark Therapeutics Is Making the Right Moves

Roger Longman, CEO of Real Endpoints, a firm assisting pharma companies with their pricing strategies, discusses the state of the value-based pricing market while lending some insights on what specialty drug companies like Spark can do to get payers on board with higher prices.

May 16, 2017

BioCentury

Contracting 2.0: The Why, When, How — And Why Not — Of Value-Based Deals

Learn why are we are seeing increasing numbers of value-based deals in the industry, how they are structured and when they make sense.

May 3, 2017

Real Endpoints' White Paper

Preferences in MS Therapy: White Paper and Literature Review

Real Endpoints, LLC (RE), a data and analytics firm that assesses and quantifies pharmaceutical value, just published a white paper and extensive literature review to tease out how different stakeholder groups (patients, payers and physicians) assess the value of current multiple sclerosis (MS) therapies.

July 31, 2016

In Vivo

Smart Segmentation/ Success In The Payer-Dominated Pharma Marketplace

As physicians lose decision-making authority to payers, drug companies need to segment markets more effectively: the patient populations prescribers are most likely to treat and that will spark the fewest access battles; and the specific payer lines-of-business least inclined to block new drugs’ use.